Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-35. (Cancelled)

36. (Currently amended) A composition comprising:

a therapeutic component comprising an alpha-2 adrenergic agonist in a therapeutically effective amount, and

an efficacy enhancing component provided in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, and to enhance the permeability of the therapeutic component, the efficacy enhancing component being present as an ion-pair complex with the therapeutic component, the ion-pair complex remaining substantially intact in an aqueous environment, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

37. (Cancelled)

38. (Cancelled)

39. (Currently amended) A composition of claim 36 wherein the alpha-2-adrenergic agonist comprises a quinoxaline component.

40. (Previously presented) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

41. (Previously presented) A composition of claim 36 wherein the therapeutic component further comprises a component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

42. (Cancelled)

43. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component comprises a fatty acid selected from the group consisting of saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

44. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component comprises a fatty acid with more than 12 carbon atoms per molecule.

45. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component comprises a docosahexanoic acid.

46. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component comprises a linoleic acid.

47. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component has a therapeutic effect.

48. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when complexed with the therapeutic component.

49. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when the efficacy enhancing component is not complexed with the therapeutic component.

50. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is effective to reduce intraocular pressure when the composition is administered to the eye.

51. (Cancelled)

52. (Cancelled)

53. (Previously presented) A composition of claim 36 wherein the complex is insoluble.

54. (Previously presented) A composition of claim 36 wherein the complex is dissociable in a biological environment to provide a therapeutic effect.

55. (Previously presented) A composition of claim 36 which includes at least one additional therapeutic component and the efficacy enhancing component is complexed with both the therapeutic component and the additional therapeutic component.

56. (Previously presented) A composition of claim 36 wherein a single therapeutic component is present in the complex with more than one efficacy enhancing component.

57. (Previously presented) A composition of claim 36 which is ophthalmically acceptable.

58. (Previously presented) A composition of claim 36 which further comprises a carrier.

59. (Currently amended) A composition comprising:

an adrenergic agonist; and

an efficacy enhancing component provided in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, and to enhance the permeability of the therapeutic component, the efficacy

enhancing component being present as an ~~effective to form~~ an ion-pair complex with the adrenergic agonist, the complex substantially remains intact in a high dielectric constant solvent, each of the enhanced effects being relative to the effect obtained with the adrenergic agonist without the efficacy enhancing component.

60. (Previously presented) A composition comprising:

an ion-pair complex including a therapeutic component comprising an adrenergic agonist, and an efficacy enhancing component, wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is present in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component; and

a carrier component which includes saline.

61. (Previously presented) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

62. (Previously presented) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

63. (Previously presented) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

64. (Previously presented) The composition of claim 60 wherein the therapeutic component further comprises a second component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

65. (Previously presented) A composition of claim 60 which has a pH of about 7 or greater.

66. (Previously presented) A composition of claim 60 which has a pH in a range of about 7 to about 9.

67. (Cancelled)

68. (Previously presented) A composition of claim 60 which is ophthalmically acceptable.

69. (Cancelled)

70. (Previously presented) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of (2-imidozolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

71. (Previously presented) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

72. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of (2-imidozolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

73. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

74. (Previously presented) A composition comprising:

a therapeutic component in a therapeutically effective amount, the therapeutic component comprising a 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, and

an efficacy enhancing component comprising a linoleic acid component, the efficacy enhancing component provided in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic

component, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

75. (Previously presented) The composition of claim 74, further comprising at least one additional therapeutic component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, alpha-2-adrenergic agonists, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

76. (Previously presented) The composition of claim 73, which has a pH of about 7 or greater.

77. (Previously presented) The composition of claim 73, further comprising at least one additional efficacy enhancing component selected from the group consisting saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

78. (Currently amended) A liquid composition comprising:

a therapeutic component in a therapeutically effective amount, and

an efficacy enhancing component provided in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, and to enhance the permeability of the therapeutic component, the efficacy enhancing component being present as a complex with the therapeutic component, the complex remaining substantially intact in an aqueous environment,

wherein the liquid composition comprising the complex has a reduced osmotic pressure relative to a substantially identical liquid composition in which the therapeutic component is not complexed with the efficacy enhancing component.

79. (Previously presented) The composition of claim 78, wherein the therapeutic component comprises a plurality of different therapeutically effective agents.

80. (Previously presented) The composition of claim 78, wherein the efficacy enhancing component comprises an anionic polymer.

81. (Previously presented) The composition of claim 78, wherein the therapeutic component and the efficacy enhancing component are provided in saline.

82. (Previously presented) The composition of claim 78, wherein the therapeutic component and the efficacy enhancing component form an ion-pair complex.

83. (Previously presented) The composition of claim 78, wherein the therapeutic component comprises an adrenergic agonist.

84. (Previously presented) The composition of claim 78, wherein the efficacy enhancing component comprises a fatty acid.

85. (Previously presented) The composition of claim 78, wherein the composition comprises a single therapeutic component and a plurality of different efficacy enhancing components.

86. (Previously presented) The composition of claim 78, wherein the composition comprises a plurality of different therapeutic components and a single efficacy enhancing component.